Edition:
United Kingdom

Seikagaku Corp (4548.T)

4548.T on Tokyo Stock Exchange

1,701JPY
7:00am BST
Change (% chg)

¥56 (+3.40%)
Prev Close
¥1,645
Open
¥1,654
Day's High
¥1,705
Day's Low
¥1,652
Volume
179,200
Avg. Vol
104,025
52-wk High
¥2,236
52-wk Low
¥1,383

Latest Key Developments (Source: Significant Developments)

Seikagaku initiates a phase III clinical trial (additional study) in the U.S. for SI-6603
Monday, 19 Feb 2018 

Feb 19 (Reuters) - Seikagaku Corp <4548.T>:Says it will initiate a Phase III clinical trial (additional study) in the U.S. for SI-6603, indicated for the treatment of radicular leg pain (i.e. sciatica) due to a lumbar disc herniation. .  Full Article

Ribomic signs collaborative research contract with SEIKAGAKU
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Ribomic Inc <4591.T>:Says it signed collaborative research contract with SEIKAGAKU CORPORATION <<<4548.T>>>.Says two entities mainly cooperate on new technologies development of drug discovery related to Aptamers.  Full Article

BRIEF-Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan

* Says it announced that the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of HERNICORE® 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation